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Abstract 
Background: Malignant pleural effusion resulting mainly from pleural metastases of lung adenocarcinoma has clini‑
cal relevance, being a sign of poor prognosis and low life expectancy. Experimental models can mimic the human 
condition, contributing to advances in current understanding of the mechanisms patients’ pleural fluid accumulation 
and possible therapeutic strategies. The objective of this study is to evaluate the role of different concentrations of 
Lewis lung carcinoma cells (LLC cells) at the time of induction of experimental MPE and the main effects on survival of 
animals.
Methods: C57BL/6 mice received intrapleural injection of 0.1, 0.5 or 1.5 × 105 LLC cells and survival curve, biochemi‑
cal and pathological analyses of pleural fluid and tissue were analyzed.
Results: Evaluation of weight loss, mobility and survival showed that animals that received 0.5 × 105 cells maintained 
more stable condition up to day 14 and a gain of 6 days survival over mice that received the highest concentration.
Conclusion: This study may allow a better understanding the mechanisms involved in the development of malig‑
nant pleural effusion and it may be promising in evaluating therapy to avoid recurrence, as the best time to indicate 
pleurodesis or target therapies.
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Background
Malignant pleural effusion (MPE) resulting from pleural 
metastasis of lung adenocarcinoma is a common clinical 
problem with severe implications, since it is a debilitating 
condition associated with high morbidity, poor prognosis 
and low life expectancy (3–15  months) [1–6]. Approxi-
mately 15 % of lung cancer patients present pleural effu-
sion at the time of diagnosis and half of them develop 
pleural effusion at disease advanced stages [1–5].
Current therapeutic options for MPE are limited to 
treatment of the primary tumor and pleural cavity drain-
age with or without pleurodesis, practices that can cause 
pain and discomfort, carry risks of adverse effects, and do 
not benefit a substantial portion of patients [7–14].
For a long time, the pathogenesis of MPE has been 
poorly understood, but substantial progress has been 
made over the past few years facilitated by the use of ani-
mal models [15–19]. These models can mimic the human 
condition, contributing to advances in current under-
standing of the mechanisms patients’ pleural fluid accu-
mulation and possible therapeutic strategies [19–27].
The objective of this study is to evaluate the role of dif-
ferent concentrations of Lewis lung carcinoma cells (LLC 
cells) at the time of induction of experimental MPE and 
the main effects on survival of animals.
The increase of survival time and delaying systemic 
effects, a better and more detailed understanding of the 
mechanisms involved in the development of malignant 
pleural effusion can be gained. This would facilitate 
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The Lewis lung carcinoma (LLC) cells were purchased 
from the American Type Culture Collection (Manassas, 
VA, USA) and were cultured at 37 °C in 5 % CO2− 95 % 
air using Dulbecco’s modiWed Eagle’s medium (DMEM) 
with 10 % fetal bovine serum.
Animal model
One hundred and thirty male (6–8 weeks old) C57BL/6 
mice (obtained from Laboratory Animal Center of Fac-
ulty of Medicine of University of São Paulo) were accli-
matized for 1  week. All animal care and experimental 
procedures were approved by the University Ethics Com-
mittee (CEUA/CAPPesq).
Animals were anesthetized using 35  mg/kg of keta-
mine hydrochloride (Cristalia, Brazil) and 5  mg/kg of 
xylazine hydrochloride (Bayer, Brazil) prior to all pro-
cedures. The right chest was cleansed with an alco-
hol solution (Rioquimica, Sao Paulo, Brazil). The 
intrapleural injection was performed using a 23-gauge 
needle attached to a 1-mL syringe containing the solu-
tion of cells which was introduced into the chest cavity 
at 1 cm lateral to the right parasternal line. The plunger 
of the syringe was removed and the needle was slowly 
advanced until it reached the pleural space, where the 
sub-atmospheric intrapleural pressure allowed the fluid 
to enter the pleural cavity spontaneously. The mice were 
monitored after the procedure until they were com-
pletely recovered.
Three groups of 40 mice each received concentrations 
of LLC at 0.1, 0.5 or 1.5 × 105 cells intrapleurally. These 
animals were subdivided into two groups; the first (30 
animals per concentration of cells) were euthanized after 
7, 14 or 21  days and the second group (10 animals per 
concentration of cells) were evaluated for survival expec-
tancy. A control group of 10 animals received saline solu-
tion intrapleurally.
Mice were killed according to the study calendar; 
the abdominal wall was opened and the viscera were 
retracted to visualize the diaphragm. Pleural fluid (PF), 
when present, was gently aspirated and the volume was 
measured and placed in tubes for evaluation.
Weight, mobility and survival analysis
After the procedure all animals were observed until com-
plete recovery and they were evaluated for weight (g) 
and mobility by a subjective score of 0–3 (0  =  normal 
and 3 =  stillness). We monitored mortality daily for all 
groups to obtain the survival curve.
Histological assays
After 7, 14 or 21  days the thorax was dissected and 
removed en bloc. A small amount of 10  % formalde-
hyde was injected through the trachea to keep the lungs 
expanded and the entire block plus kidney, liver and 
spleen were placed in 10 % formaldehyde. After at least 
24  h in formaldehyde, the pleural cavities were opened 
and exposed through longitudinal chest incisions at the 
mid-clavicular lines. Tissues were fixed in 10 % neutrally 
buffered formalin for 24 h and 70 % ethanol for 3 days. 
In sequence, they were embedded in paraffin, and 5-μm 
thick slices were cut, mounted on slides and stained with 
hematoxylin and eosin (H&E).
Biochemical assays
Lactic dehydrogenase (kinetic UV method) and total pro-
tein (Biuret method) were quantified in the pleural fluid 
using commercial kits (Wienner, Argentina) and ana-
lyzed in semi-automatic device.
Cytology
Pleural fluid cells were counted in a Neubauer chamber. 
After centrifugation, cells cytospin were prepared and the 
slides were air dried and stained using Leishman staining 
to determine the cell differential.
Statistics
The results are presented as mean and standard devia-
tion. Comparisons among the groups were performed 
using ANOVA followed by the comparison multiple test. 
For the survival time, Kaplan–Meier curves were estab-
lished for each group and the times were compared using 
a log-rank test. A value of p < 0.05 was considered signifi-
cant. SigmaStat 3.1 (Systat, CA, USA) was used for the 
analyses.
Results
After the intrapleural injection of different concentra-
tions of LLC cells, all animals presented tumor implan-
tation with development of malignant pleural effusion 
showing differences among them according to the time 
and stage of disease. Free-floating bilateral pleural effu-
sions and pleural tumor foci were clearly visible through 
the diaphragm. Interestingly, in the majority of mice that 
received 0.1  ×  105 cells, minimal or absence of pleural 
fluid and few tumoral implants were observed until the 
14th day.
Evaluation of body weight and mobility showed that 
mice in the group of 1.5 × 105 cells had reduced weight 
and mobility after 14  days while in the other groups, 
these differences were noted only after 21 days (p < 0.05).
In the survival analysis, pleural carcinomatosis was 
lethal in all groups. In the group of highest concentration 
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(1.5 × 105 cells) the mortality was 100 % on the 19th day 
while the groups of 0.5 and 0.1 × 105 cells showed maxi-
mum survival of 25 and 27 days, respectively (Fig. 1).
Pleural fluid volume was measured at 7, 14 and 21 days. 
The volume was increasing significantly according to 
the time and LLC cells concentration (p  <  0.05); group 
0.1 × 105 cells showed pleural effusion only after 14 days 
in few animals and for group 1.5 × 105 cells, evaluation 
was only possible up to the 14th day (all animals died 
by day 19) (Fig.  2). In the control group (saline intra-
pleurally), we do not observe pleural fluid accumulation.
The macroscopic aspect of most pleural fluid was hem-
orrhagic (but did not coagulate). By harvesting mice at 
serial time points we observed that malignant pleural 
effusion was formed gradually and that their red blood 
cell content increased stepwise.
Total cells count was progressively increasing up to 
14 day being more evident in highest concentrations (0.5 
and 1.5 × 105) (Fig. 2). MPE differential cells revealed a 
mixed inflammatory infiltrate interspersed with malig-
nant cells. The inflammatory cell population consisted of 
mononuclear cells (60 %), lymphocytes (20 %) and neu-
trophils (10 %). Mesothelial cells accounted for less than 
1 % of cells.
Pleural fluid LDH levels were higher proportional 
to the time (p  <  0.001) and concentration (p  <  0.05) of 
injected LLC cells. Protein levels were similar among 
groups excepted at 7  days in 0.1 ×  105 LLC cells group 
(Fig. 2).
Tumor implants in the pleura were evident earlier 
in groups that received a larger concentration of LLC 
cells. The presence of loose tumors in the pleural space 
was also noted in all study groups at 7 days except in the 
group with the lowest concentration of LLC cells. Larger 
pleural tumors formed bridges between the lung paren-
chyma and the thoracic cage and infiltrated neighboring 
anatomic structures, including the chest wall, mediasti-
num, and diaphragm (Fig. 3). In group 1.5 × 105 LLC cells 
numerous tumor implants were observed in the visceral 
and parietal pleura after 7  days of exposure. In group 
0.5 × 105 cells LLC we noted few dispersed implants at 
day 7 with more pronounced implantation after 14 days. 
In animals receiving lower cells concentration, tumor 
implants were only observed after 14 days (Fig. 3).
Neoplastic infiltration of lung parenchyma was 
observed only in few animals with no correlation with 
the dose or exposure time. However, lung parenchymal 
inflammation was unremarkable in all groups over all 
check points; there was no inflammatory focus at con-
centration 0.1 × 105 cells on day 7.
Histological evaluation of pericardium and heart 
muscle showed tumor implants in the first 7  days after 
injection of 1.5 × 105 LLC cells with increased progres-
sion over time. In the other concentrations few tumor 
implants were observed during the study (Fig. 4).
In the liver, micro foci of steatosis were observed after 
14 days at concentrations 1.5 and 0.5 × 105 LLC cells. No 
relevant histological changes were observed in the renal 
evaluation. Hyperplasia of the white pulp of the spleen 
was observed at all evaluation time points with greater 
evidence at concentrations of 1.5 and 0.5 × 105 LLC cells 
(Fig. 4).
Fig. 1 Mice survival time evaluation with intrapleural injection of 0.1, 0.5 or 1.5 × 105 LLC cells
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Discussion
This study evaluated the survival curve, laboratorial and 
histological aspects in an experimental murine model of 
MPE using different concentrations of LLC cells. Evalu-
ation of weight loss, mobility and survival at the higher 
concentrations (0.5 and 1.5 × 105 cells) showed that ani-
mals that received 0.5 ×  105 cells maintained more sta-
ble condition up to day 14. The survival curve shows a 
gain of 6 days survival over mice that received the high-
est concentration. We found MPE from day 7 and several 
tumor foci in both the visceral and parietal pleura in the 
higher concentration groups. However, minimal or no 
volume of pleural fluid and few implants were observed 
in the smaller LLC concentration group at day 14.
Lung cancer is the most common cause of worldwide 
cancer-related mortality, leading to over a million deaths 
each year and adenocarcinoma is its most common histo-
logical type [1–5]. In this scenario, MPE resulting mainly 
from pleural metastases of lung adenocarcinoma has 
clinical relevance [4, 14]. Its emergence is a sign of poor 
prognosis and low life expectancy, as it indicates that 
the tumor is incurable by surgery [4]. Dyspnea occurs in 
more than 50 % of patients, severely compromising their 
quality of life. In spite of the therapeutic advances since 
the platinum-based schemes, lung cancer treatment does 
not significantly impact the disease evolution of most 
patients [4–14].
New therapeutic strategies are needed to improve local 
control and the spread of cancer, but this requires greater 
insight into the pathogenesis of this disease.
Until some time ago, there were a few experimental 
models for the study of pleural neoplasms, most using 
Fig. 2 Volume, total cells count and biochemical parameters of malignant pleural effusion in mice injected with 0.1, 0.5 and 1.5 × 105 LLC cells. 
*p < 0.05, **p < 0.001, ***p < 0.001 and #p < 0.05 when compared the groups
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Fig. 3 Histology of pleura, lung parenchyma and diaphragm of mice that received intrapleural injection of LLC cells. a Pleura and lung parenchyma 
after 7 days of 0.1 × 105 cells; b tumor implantation in visceral pleura after 7 days of 0.5 × 105 cells (arrows); c tumor implants in visceral pleura after 
14 days of 0.5 × 105 cells (arrows); d tumor implants in visceral pleura after 14 days of 1.5 × 105 cells (asterisk); e massive tumor invading diaphragm 
after 14 days of 1.5 × 105 cells (asterisk); f tumor mass observed after 21 days of LLC cells (asterisk). Hematoxylin & eosin staining. LP lung paren‑
chyma, asterisk tumor, arrows tumor implants
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Fig. 4 Histology of organs of mice that received intrapleural injection of LLC cells. a Tumor implants in pericardium after 7 days of 1.5 × 105 cells 
(arrows); b neoplastic cells infiltrating the myocardium (asterisk) after 14 days of 1.5 × 105 cells; c normal liver after 7 days of 0.5 × 105 cells; d liver 
with steatosis (filled triangle) after 14 days of LLC cells; e, f kidney with tubular steatosis (filled triangle) and without neoplastic cells after 7 or 14 days. 
g, h Reactive spleen (filled circle) without neoplastic cells after 7 and 14 days. Hematoxylin & eosin staining
Page 7 of 8Acencio et al. J Transl Med  (2015) 13:302 
animals with normal pleura to test palliative therapies 
such as pleurodesis [24–26]. In the absence of malig-
nant disease assessment of the natural evolution of the 
cancer, neoplasia-host interactions, or possible immune 
response is obviously not possible [25, 26]. Therefore, 
some researchers have developed novel models of MPE 
with a more accurate mimicry of the human condition. 
These models have contributed to significant advances 
in the understanding of fluid exudation induced by can-
cer metastasis to the pleura [19]. They have yielded novel 
insights into the pathogenesis of adenocarcinoma as well 
as into the mechanisms of intrapleural malignant effu-
sion accumulation, tumor dissemination and possible 
therapeutic targets to block pleural effusion [19].
In 2006, Stathopoulos et  al. developed and character-
ized a novel mouse model of malignant pleural effusion 
by injecting 1.5 × 105 Lewis lung carcinoma (LLC) cells 
directly into the pleural space of immunocompetent 
C57BL/6 mice [20].
LLC cells are derived from a spontaneously arising lung 
adenocarcinoma in C57BL/6 mice. These cells are char-
acterized by short doubling times in vitro and in vivo and 
aggressive biological behavior [19–21]. The cells can be 
propagated in C57BL/6 mice, giving rise to lung adeno-
carcinoma and human-like MPEs producing exudates 
with high protein and LDH content, as well as high lev-
els of VEGF and monocyte chemoattractant chemokines 
[19–21].
This LLC-C57BL/6 model is highly reproducible since 
it uses immunocompetent animals, closely resembles 
human MPEs and provides reproducible end-points. It 
can be used to study the influence of specific host and 
tumor factors on the pathogenesis of MPE and to eval-
uate new therapeutic strategies. In addition, all of the 
animals get MPE and intense tumor foci on visceral and 
parietal pleura in 14 days [20].
Nevertheless, the maximum survival of the animals in 
the Stathopoulos et al. model was 17 days, an unfavorable 
point, since survival is an important outcome measure 
and so few days may not be sufficient to assess outcome 
[20, 21].
Also, in these studies authors observed a correlation 
between the number of pleural tumor foci and the vol-
ume of pleural fluid. They discussed the importance of 
the host immune response, which is partly responsible 
for the malignant pleural fluid accumulation [20–23]. 
These issues are directly relevant in studies to investigate 
the pathogenesis and treatment of MPEs. The pleural 
fluid accumulation remains the primary end-point in this 
model; however, determinations relevant to these bio-
processes may serve as additional end-points in animal 
models of MPE.
The cellular and biochemical profile of pleural effu-
sion resulting from induced lung adenocarcinoma mim-
ics human MPE, which is high in protein and LDH levels 
and nucleated cells with neoplastic cells permeating a 
rich inflammatory infiltrates. Implantation and growth 
of pleural tumors triggers a host inflammatory response 
characterized by a mixed inflammatory cell influx into 
the pleural fluid, angiogenesis, and vascular hyperper-
meability, all fundamental steps in MPE pathogenesis 
[19–21].
We found tumors implants in the visceral and parietal 
pleura in all groups studied and they were proportional 
to the concentration and time from instillation of LLC 
cells. Metastasis to the pericardium was more evident 
at the highest concentration. Inflammatory lung paren-
chyma cells and histological changes in the liver, kidneys 
and spleen were observed in all groups with the highest 
scores in groups 0.5 and 1.5 × 105 cells.
Furthermore, induction of MPE in animals leads to 
cachexia, which can serve as a surrogate marker of tumor 
progression. In our study mice that received 0.5  ×  105 
LLC cells maintained more stable condition through day 
14 compared to mice that received the highest concentra-
tion, resulting in a longer survival.
One limitation of our study was related to the assess-
ment of animals at 21 days due to the fact that most died 
before analysis could be done.
Conclusions
Our results show that using a dose of 0.5  ×  105 cells 
LLC is possible not only to induce the disease as well 
as to better evaluate survival time, without prejudice to 
the model proposed initially by Stathophoulous and col-
leagues [20]. With this cell concentration we obtained a 
model that allowed for monitoring longer survival, the 
study of pleuropulmonary changes and to assess local 
and distant metastases, opening a fantastic range of study 
opportunities.
This study may allow a better understanding the mech-
anisms involved in the development of malignant pleural 
effusion. In addition, it may be promising in evaluating 
therapy responses, the best time to indicate pleurodesis, 
as well as, to consider the response to immunomodula-
tory therapies, costs and benefits of targeted therapies.
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